CEFTRIAXONE sodium, eq. 250mg base, powder, vial
STD
DINJCEFT2V-
Valid Article
Account code:
60000
HS Code:
300420
Last Updated on:
07/11/2024, 18:34:10
Former
Code(s):
-X
6.2.2 - Watch group antibiotics
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
J01DD04
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
CEFTRIAXONE
Therapeutic Action
Third-generation cephalosporin antibacterial
Indications
Severe bacterial infections (meningitis, pneumonia, typhoid fever, shigellosis, leptospirosis, tick-borne relapsing fevers, pyelonephritis, neurosyphilis, etc.)
Cervicitis, urethritis and conjunctivitis due to Neisseria gonorrhoeae, chancroid
- See: Essential drugs, MSF, 2024
- See: Clinical guidelines, MSF, 2024
- See: Neonatal care, Clinical and Therapeutic guidelines, MSF, 2021
- See: Medical protocol for Sexual Violence Care, MSF, 2022
- See: Pathogen-Specific, Targeted Antibiotic Therapy for Bacteremia and Bone and Joint, Urinary Tract, and Central Nervous System Infections. MSF internal protocol, 2019
Instructions for use
Reconstitute the powder vial with water for injection.
The reconstituted solution must be given as slow IV injection or infusion in 0.9% NaCl or 5% dextrose.
The 250 mg dosage is intended for paediatric use.
Precautions for Use
Do not mix ceftriaxone with calcium-containing solutions (such as ringer lactate): risk of particulate formation.
Do not confuse with ceftriaxone + lidocaine administered by IM route only.
Storage
- Below 25°C - Protect from sunlight
- After reconstitution, use the solution immediately.